1
|
Belfiore A, Busico A, Bozzi F, Brich S, Dallera E, Conca E, Capone I, Gloghini A, Volpi CC, Cabras AD, Pilotti S, Baratti D, Guaglio M, Deraco M, Kusamura S, Perrone F. Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma. Int J Mol Sci 2019; 20:ijms20225817. [PMID: 31752449 PMCID: PMC6888071 DOI: 10.3390/ijms20225817] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2019] [Revised: 11/08/2019] [Accepted: 11/15/2019] [Indexed: 12/15/2022] Open
Abstract
Background—There are currently no effective therapies for diffuse malignant peritoneal mesothelioma (DMPM) patients with disease recurrence. In this study, we investigated the biology of DMPM by analyzing the EGFR family, Axl, and MET, in order to assess the presence of cross-talk between these receptors, suggesting the effectiveness of combined targeted treatments in DMPM. Method—We analyzed a series of 22 naïve epithelioid DMPM samples from a single institute, two of which showed higher-grade malignancy (“progressed”). EGFR, HER2, HER3, Axl, and MET activation and expression were investigated by biochemical analysis, real-time PCR immunofluorescence, immunohistochemistry, next-generation sequencing, miRNA, and mRNA in situ hybridization. Results—In most DMPMs, a strong EGFR activation was associated with HER2, HER3, Axl, and MET co-activation, mediated mainly by receptor heterodimerization and autocrine-paracrine loops induced by the expression of their cognate ligands. Axl expression was downregulated by miRNA34a. Mutations in MET Sema domain were exclusively found in two “progressed” DMPMs, and the combined Axl and MET inhibition reduced cellular motility in a DMPM cell line obtained from a “progressed” DMPM. Conclusion—The results indicate that the coordinated activity of multiple cross-talks between RTKs is directly involved in the biology of DMPM, suggesting the combined inhibition of PIK3 and mTOR as an effective strategy that may be easily implemented in clinical practice, and indicating that the combined inhibition of EGFR/HER2 and HER3 and of Axl and MET deserves further investigation.
Collapse
Affiliation(s)
- Antonino Belfiore
- Laboratory of Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy; (A.B.); (A.B.); (F.B.); (S.B.); (E.D.); (E.C.); (I.C.); (A.G.); (C.C.V.); (S.P.)
| | - Adele Busico
- Laboratory of Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy; (A.B.); (A.B.); (F.B.); (S.B.); (E.D.); (E.C.); (I.C.); (A.G.); (C.C.V.); (S.P.)
| | - Fabio Bozzi
- Laboratory of Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy; (A.B.); (A.B.); (F.B.); (S.B.); (E.D.); (E.C.); (I.C.); (A.G.); (C.C.V.); (S.P.)
| | - Silvia Brich
- Laboratory of Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy; (A.B.); (A.B.); (F.B.); (S.B.); (E.D.); (E.C.); (I.C.); (A.G.); (C.C.V.); (S.P.)
| | - Elena Dallera
- Laboratory of Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy; (A.B.); (A.B.); (F.B.); (S.B.); (E.D.); (E.C.); (I.C.); (A.G.); (C.C.V.); (S.P.)
| | - Elena Conca
- Laboratory of Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy; (A.B.); (A.B.); (F.B.); (S.B.); (E.D.); (E.C.); (I.C.); (A.G.); (C.C.V.); (S.P.)
| | - Iolanda Capone
- Laboratory of Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy; (A.B.); (A.B.); (F.B.); (S.B.); (E.D.); (E.C.); (I.C.); (A.G.); (C.C.V.); (S.P.)
| | - Annunziata Gloghini
- Laboratory of Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy; (A.B.); (A.B.); (F.B.); (S.B.); (E.D.); (E.C.); (I.C.); (A.G.); (C.C.V.); (S.P.)
| | - Chiara C. Volpi
- Laboratory of Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy; (A.B.); (A.B.); (F.B.); (S.B.); (E.D.); (E.C.); (I.C.); (A.G.); (C.C.V.); (S.P.)
| | - Antonello D. Cabras
- Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy;
| | - Silvana Pilotti
- Laboratory of Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy; (A.B.); (A.B.); (F.B.); (S.B.); (E.D.); (E.C.); (I.C.); (A.G.); (C.C.V.); (S.P.)
| | - Dario Baratti
- Peritoneal Surface Malignancy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy; (D.B.); (M.G.); (M.D.); (S.K.)
| | - Marcello Guaglio
- Peritoneal Surface Malignancy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy; (D.B.); (M.G.); (M.D.); (S.K.)
| | - Marcello Deraco
- Peritoneal Surface Malignancy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy; (D.B.); (M.G.); (M.D.); (S.K.)
| | - Shigeki Kusamura
- Peritoneal Surface Malignancy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy; (D.B.); (M.G.); (M.D.); (S.K.)
| | - Federica Perrone
- Laboratory of Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy; (A.B.); (A.B.); (F.B.); (S.B.); (E.D.); (E.C.); (I.C.); (A.G.); (C.C.V.); (S.P.)
- Correspondence: ; Tel.: +39-02-2390-2614; Fax: +39-02-2390-2877
| |
Collapse
|
2
|
Cavalieri S, Busico A, Capone I, Conca E, Dallera E, Quattrone P, Licitra L, Pruneri G, Bossi P, Perrone F. Identification of potentially druggable molecular alterations in skin adnexal malignancies. J Dermatol 2019; 46:507-514. [DOI: 10.1111/1346-8138.14889] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2018] [Accepted: 03/21/2019] [Indexed: 12/18/2022]
Affiliation(s)
- Stefano Cavalieri
- Head and Neck Medical Oncology Unit Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Milan Italy
| | - Adele Busico
- Department of Pathology Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Milan Italy
| | - Iolanda Capone
- Department of Pathology Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Milan Italy
| | - Elena Conca
- Department of Pathology Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Milan Italy
| | - Elena Dallera
- Department of Pathology Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Milan Italy
| | - Pasquale Quattrone
- Department of Pathology Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Milan Italy
| | - Lisa Licitra
- Head and Neck Medical Oncology Unit Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Milan Italy
- University of Milan Milan Italy
| | - Giancarlo Pruneri
- Department of Pathology Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Milan Italy
- University of Milan Milan Italy
| | - Paolo Bossi
- Head and Neck Medical Oncology Unit Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Milan Italy
| | - Federica Perrone
- Department of Pathology Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Milan Italy
| |
Collapse
|
3
|
Vanoli A, Di Sabatino A, Martino M, Dallera E, Furlan D, Mescoli C, Macciomei MC, Biancone L, Neri B, Grillo F, Biletta E, Rugge M, Sessa F, Paulli M, Corazza GR, Solcia E. Epstein-Barr virus-positive ileal carcinomas associated with Crohn’s disease. Virchows Arch 2017; 471:549-552. [DOI: 10.1007/s00428-017-2209-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2017] [Revised: 06/20/2017] [Accepted: 07/20/2017] [Indexed: 12/11/2022]
|
4
|
Perfetti V, Laurini E, Aulić S, Fermeglia M, Riboni R, Lucioni M, Dallera E, Delfanti S, Pugliese L, Latteri FS, Pietrabissa A, Pricl S. Molecular and functional characterization of a new 3' end KIT juxtamembrane deletion in a duodenal GIST treated with neoadjuvant Imatinib. Oncotarget 2017; 8:56158-56167. [PMID: 28915580 PMCID: PMC5593551 DOI: 10.18632/oncotarget.19341] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2017] [Accepted: 06/28/2017] [Indexed: 12/11/2022] Open
Abstract
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. GISTs express the receptor tyrosine kinase KIT, and the majority of GISTs present KIT gain-of-function mutations that cluster in the 5′ end of the receptor juxtamembrane domain. On the other hand, little information is known about GISTs carrying mutations in the 3′ end of the KIT juxtamembrane domain. Here we report and discuss a clinical case of localized duodenal GIST whose molecular characterization revealed the presence of a new 21 nucleotide/7 amino acid deletion in the 3′ end of KIT juxtamembrane domain (Δ574–580). The patient was treated with Imatinib at standard regimen dose (400 mg/day), and responded well as the original tumor mass reduced, ultimately allowing conservative surgery. In line with these clinical evidences computer simulations, biophysical techniques and in vitro experiments demonstrated that the receptor tyrosine kinase KIT carrying the Δ574–580 mutation displays constitutive phosphorylation, which can be switched-off upon Imatinib treatment. In addition, results from this study showed that a clinical useful procedure, neoadjuvant treatment, can occasionally be of value for the understanding of the molecular pathogenesis of GIST.
Collapse
Affiliation(s)
- Vittorio Perfetti
- Internal Medicine, Ospedale SS Annunziata-ASST Pavia and Department of Molecular Medicine University of Pavia, 27100 Pavia, Italy
| | - Erik Laurini
- Molecular Simulation Engineering (MOSE) Laboratory, Pharmaceutical and Molecular Biology Division, DEA, University of Trieste, 34127 Trieste, Italy
| | - Suzana Aulić
- Molecular Simulation Engineering (MOSE) Laboratory, Pharmaceutical and Molecular Biology Division, DEA, University of Trieste, 34127 Trieste, Italy
| | - Maurizio Fermeglia
- Molecular Simulation Engineering (MOSE) Laboratory, Pharmaceutical and Molecular Biology Division, DEA, University of Trieste, 34127 Trieste, Italy
| | - Roberta Riboni
- Department of Molecular Medicine and Anatomic Pathology Section, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
| | - Marco Lucioni
- Department of Molecular Medicine and Anatomic Pathology Section, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
| | - Elena Dallera
- Department of Molecular Medicine and Anatomic Pathology Section, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
| | - Sara Delfanti
- Department of Oncology and Hematology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
| | - Luigi Pugliese
- Department of Surgery, General Surgery II, University of Pavia and Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
| | | | - Andrea Pietrabissa
- Department of Surgery, General Surgery II, University of Pavia and Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
| | - Sabrina Pricl
- Molecular Simulation Engineering (MOSE) Laboratory, Pharmaceutical and Molecular Biology Division, DEA, University of Trieste, 34127 Trieste, Italy
| |
Collapse
|
5
|
Lucioni M, Berti E, Arcaini L, Croci GA, Maffi A, Klersy C, Goteri G, Tomasini C, Quaglino P, Riboni R, Arra M, Dallera E, Grandi V, Alaibac M, Ramponi A, Rattotti S, Cabras MG, Franceschetti S, Fraternali-Orcioni G, Zerbinati N, Onida F, Ascani S, Fierro MT, Rupoli S, Gambacorta M, Zinzani PL, Pimpinelli N, Santucci M, Paulli M. Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers. Cancer Med 2016; 5:2740-2755. [PMID: 27665744 PMCID: PMC5083727 DOI: 10.1002/cam4.865] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2016] [Revised: 06/30/2016] [Accepted: 07/16/2016] [Indexed: 11/21/2022] Open
Abstract
Categorization of primary cutaneous B‐cell lymphomas (PCBCL) other than marginal zone (MZL) represents a diagnostic challenge with relevant prognostic implications. The 2008 WHO lymphoma classification recognizes only primary cutaneous follicular center cell lymphoma (PCFCCL) and primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL‐LT), whereas the previous 2005 WHO/EORTC classification also included an intermediate form, namely PCDLBCL, other. We conducted a retrospective, multicentric, consensus‐based revision of the clinicopathologic characteristics of 161 cases of PCBCL other than MZL. Upon the histologic features that are listed in the WHO classification, 96 cases were classified as PCFCCL and 25 as PCDLBCL‐LT; 40 further cases did not fit in the former subgroups in terms of cytology and/or architecture, thus were classified as PCDLBCL, not otherwise specified (PCDLBCL‐NOS). We assigned all the cases a histogenetic profile, based on the immunohistochemical detection of CD10, BCL6, and MUM1, and a “double hit score” upon positivity for BCL2 and MYC. PCDLBCL‐NOS had a clinical presentation more similar to PCFCCL, whereas the histology was more consistent with the picture of a diffuse large B‐cell lymphoma, as predominantly composed of centroblasts but with intermixed a reactive infiltrate of small lymphocytes. Its behavior was intermediate between the other two forms, particularly when considering only cases with a “non‐germinal B‐cell” profile, whereas “germinal center” cases resembled PCFCCL. Our data confirmed the aggressive behavior of PCDLBC‐LT, which often coexpressed MYC and BCL2. The impact of single factors on 5‐year survival was documented, particularly histogenetic profile in PCDLBCL and BCL2 translocation in PCFCCL. Our study confirms that a further group—PCDLBCL‐NOS—exists, which can be recognized through a careful combination of histopathologic criteria coupled with adequate clinical information.
Collapse
Affiliation(s)
- Marco Lucioni
- Unit of Anatomic Pathology, Department of Molecular Medicine, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Emilio Berti
- Department of Dermatology, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico and Università degli Studi di Milano-Bicocca, Milan, Italy
| | - Luca Arcaini
- Section of Hematology-Oncology, Department of Molecular Medicine, University of Pavia, Pavia, Italy
| | - Giorgio A Croci
- Unit of Anatomic Pathology, Department of Molecular Medicine, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Aldo Maffi
- Unit of Anatomic Pathology, Department of Molecular Medicine, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Catherine Klersy
- Scientific Direction, Biometry and Statistics, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Gaia Goteri
- Pathologic Anatomy and Histopathology, Department of Biomedical Sciences and Public Health, Polytechnic University of Marche Region, United Ancona Hospitals, Torrette, Ancona, Italy
| | - Carlo Tomasini
- Pathology Unit, Department of Laboratory Medicine, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Turin, Italy
| | - Pietro Quaglino
- Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Roberta Riboni
- Unit of Anatomic Pathology, Department of Molecular Medicine, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Mariarosa Arra
- Unit of Anatomic Pathology, Department of Molecular Medicine, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Elena Dallera
- Unit of Anatomic Pathology, Department of Molecular Medicine, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Vieri Grandi
- Division of Dermatology, University of Florence Medical School, Florence, Italy
| | - Mauro Alaibac
- Dermatologic Clinic, University of Padova, Padova, Italy
| | - Antonio Ramponi
- Division of Pathology, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy
| | - Sara Rattotti
- Department of Hematology and Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | | | - Silvia Franceschetti
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy
| | | | - Nicola Zerbinati
- Department of Surgical and Morphological Sciences, Faculty of Medicine and Surgery, University of Insubria, Varese, Italy
| | - Francesco Onida
- Hematology and Bone Marrow Transplantation Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and University of Milan, Milano, Italy
| | - Stefano Ascani
- Institute of Pathology, Ospedale S. Maria di Terni and University of Perugia, Perugia, Italy
| | - Maria Teresa Fierro
- Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Serena Rupoli
- Clinic of Hematology, United Ancona Hospitals, Torrette, Ancona, Italy
| | | | - Pier Luigi Zinzani
- Institute of Hematology "Seràgnoli", University of Bologna, Bologna, Italy
| | - Nicola Pimpinelli
- Division of Dermatology, University of Florence Medical School, Florence, Italy
| | - Marco Santucci
- Division of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence School of Human Health Sciences, Firenze, Italy
| | - Marco Paulli
- Unit of Anatomic Pathology, Department of Molecular Medicine, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
| |
Collapse
|
6
|
Perfetti V, Delfanti S, Pugliese L, Riboni R, Dallera E, Lucioni M, Rognoni P, Latteri F, Pedrazzoli P, Pietrabissa A. Neoadjuvant treatment of a duodenal GIST revealed a new imatinib-sensitive exon 11 c-KIT-mutation. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw343.08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
7
|
Perfetti V, Baldanti F, Lenti MV, Vanoli A, Biagi F, Gatti M, Riboni R, Dallera E, Paulli M, Pedrazzoli P, Corazza GR. Detection of Active Epstein-Barr Virus Infection in Duodenal Mucosa of Patients With Refractory Celiac Disease. Clin Gastroenterol Hepatol 2016; 14:1216-20. [PMID: 27033429 DOI: 10.1016/j.cgh.2016.03.022] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/28/2015] [Revised: 02/22/2016] [Accepted: 03/16/2016] [Indexed: 02/07/2023]
Abstract
Refractory celiac disease is characterized by mucosal damage in patients with celiac disease despite a gluten-free diet. Little is known about the mechanisms that cause persistent intestinal inflammation in these patients. We performed a case-control study of 17 consecutive patients diagnosed with refractory celiac disease from 2001 through 2014 (median age, 51 y; 10 women) and 24 patients with uncomplicated celiac disease (controls) to determine whether refractory disease is associated with infection by lymphotropic oncogenic viruses. We performed real-time PCR analyses of duodenal biopsy samples from all patients to detect Epstein-Barr virus (EBV), human herpesvirus-8, and human T-cell lymphotropic virus-I, -II, or -III. We used in situ hybridization and immunohistochemical analyses to identify infected cells and viral proteins. We did not detect human herpesvirus-8 or human T-cell lymphotropic viruses in any of the biopsy specimens. However, 12 of 17 (70.5%) biopsy specimens from patients with refractory celiac disease were positive for EBV, compared with 4 of 24 (16.6%) biopsy specimens from controls (P < .001). EBV was detected in inflammatory cells and enterocytes. An analysis of latency- and replication-associated proteins confirmed active infection. Further studies are needed to determine whether EBV infection contributes to the pathogenesis of refractory celiac disease and enteropathy-associated T-cell lymphoma.
Collapse
Affiliation(s)
- Vittorio Perfetti
- Department of Onco-Hematology, Section of Oncology, University of Pavia and Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy
| | - Fausto Baldanti
- Molecular Virology Unit, University of Pavia and Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy
| | - Marco Vincenzo Lenti
- First Department of Internal Medicine, University of Pavia and Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy
| | - Alessandro Vanoli
- Department of Molecular Medicine and Anatomic Pathology section, University of Pavia and Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy
| | - Federico Biagi
- First Department of Internal Medicine, University of Pavia and Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy
| | - Marta Gatti
- Molecular Virology Unit, University of Pavia and Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy
| | - Roberta Riboni
- Department of Molecular Medicine and Anatomic Pathology section, University of Pavia and Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy
| | - Elena Dallera
- Department of Molecular Medicine and Anatomic Pathology section, University of Pavia and Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy
| | - Marco Paulli
- Department of Molecular Medicine and Anatomic Pathology section, University of Pavia and Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy
| | - Paolo Pedrazzoli
- Department of Onco-Hematology, Section of Oncology, University of Pavia and Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy
| | - Gino Roberto Corazza
- First Department of Internal Medicine, University of Pavia and Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy.
| |
Collapse
|
8
|
Fiorina L, Ricotti M, Vanoli A, Luinetti O, Dallera E, Riboni R, Paolucci S, Brugnatelli S, Paulli M, Pedrazzoli P, Baldanti F, Perfetti V. Systematic analysis of human oncogenic viruses in colon cancer revealed EBV latency in lymphoid infiltrates. Infect Agent Cancer 2014; 9:18. [PMID: 24936208 PMCID: PMC4058445 DOI: 10.1186/1750-9378-9-18] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2013] [Accepted: 04/28/2014] [Indexed: 12/16/2022] Open
Abstract
Background Environmental factors may play a role in colon cancer. In this view, several studies investigated tumor samples for the presence of various viral DNA with conflicting results. Findings We undertook a systematic DNA analysis of 44 consecutive, prospectively collected primary tumor samples by real time and qualitative PCR for viruses of known or potential oncogenic role in humans, including polyomavirus (JCV, BKV, Merkel cell polyomavirus), HPV, HTLV, HHV-8 and EBV. Negative controls consisted of surgical resection margins. No evidence of genomic DNA fragments from tested virus were detected, except for EBV, which was found in a significant portion of tumors (23/44, 52%). Real-time PCR showed that EBV DNA was present at a highly variable content (median 258 copies in 105 cells, range 15–4837). Presence of EBV DNA had a trend to be associated with high lymphocyte infiltration (p = 0.06, χ2 test), and in situ hybridization with EBER1-2 probes revealed latency in a fraction of these lymphoid cells, with just a few scattered plasma cells positive for BZLF-1, an immediate early protein expressed during lytic replication. LMP-1 expression was undetectable by immunohistochemistry. Conclusions These results argue against a significant involvement of the tested oncogenic viruses in established colon cancer.
Collapse
Affiliation(s)
- Loretta Fiorina
- Department of Diagnostic Medicine, Molecular Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Mattia Ricotti
- Department of Onco-Hematology, Oncology Section, Fondazione IRCCS Policlinico San Matteo, V.le Camillo Golgi 19, 27100 Pavia, Italy
| | - Alessandro Vanoli
- Department of Molecular Medicine, University of Pavia and Anatomic Pathology section, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Ombretta Luinetti
- Department of Molecular Medicine, University of Pavia and Anatomic Pathology section, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Elena Dallera
- Department of Molecular Medicine, University of Pavia and Anatomic Pathology section, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Roberta Riboni
- Department of Molecular Medicine, University of Pavia and Anatomic Pathology section, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Stefania Paolucci
- Department of Diagnostic Medicine, Molecular Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Silvia Brugnatelli
- Department of Onco-Hematology, Oncology Section, Fondazione IRCCS Policlinico San Matteo, V.le Camillo Golgi 19, 27100 Pavia, Italy
| | - Marco Paulli
- Department of Molecular Medicine, University of Pavia and Anatomic Pathology section, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Paolo Pedrazzoli
- Department of Onco-Hematology, Oncology Section, Fondazione IRCCS Policlinico San Matteo, V.le Camillo Golgi 19, 27100 Pavia, Italy
| | - Fausto Baldanti
- Department of Diagnostic Medicine, Molecular Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Vittorio Perfetti
- Department of Onco-Hematology, Oncology Section, Fondazione IRCCS Policlinico San Matteo, V.le Camillo Golgi 19, 27100 Pavia, Italy
| |
Collapse
|
9
|
Fiandrino G, Arra M, Riboni R, Lucioni M, Dallera E, Arcaini L, Berti E, Paulli M. Absence ofMYD88L265P mutation in blastic plasmacytoid dendritic cell neoplasm. Br J Dermatol 2013; 168:883-4. [DOI: 10.1111/bjd.12061] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|